XOMETRY INC-A (XMTR)

US98423F1093 - Common Stock

17.53  +0.61 (+3.61%)

After market: 17.53 0 (0%)

Fundamental Rating

3

Overall XMTR gets a fundamental rating of 3 out of 10. We evaluated XMTR against 51 industry peers in the Trading Companies & Distributors industry. While XMTR seems to be doing ok healthwise, there are quite some concerns on its profitability. XMTR is valued quite expensive, but it does show an excellent growth.



1

1. Profitability

1.1 Basic Checks

In the past year XMTR has reported negative net income.
XMTR had a negative operating cash flow in the past year.
XMTR had negative earnings in each of the past 5 years.
XMTR had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

XMTR has a worse Return On Assets (-9.54%) than 88.24% of its industry peers.
The Return On Equity of XMTR (-20.48%) is worse than 86.27% of its industry peers.
Industry RankSector Rank
ROA -9.54%
ROE -20.48%
ROIC N/A
ROA(3y)-10.69%
ROA(5y)-23.39%
ROE(3y)-18.43%
ROE(5y)-40.07%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

XMTR has a Gross Margin of 38.48%. This is in the better half of the industry: XMTR outperforms 64.71% of its industry peers.
In the last couple of years the Gross Margin of XMTR has grown nicely.
XMTR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 38.48%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.77%
GM growth 5YN/A

4

2. Health

2.1 Basic Checks

XMTR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for XMTR has been increased compared to 1 year ago.
XMTR has a worse debt/assets ratio than last year.

2.2 Solvency

XMTR has an Altman-Z score of 1.45. This is a bad value and indicates that XMTR is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 1.45, XMTR is not doing good in the industry: 68.63% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.86 indicates that XMTR is somewhat dependend on debt financing.
XMTR has a Debt to Equity ratio (0.86) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.86
Debt/FCF N/A
Altman-Z 1.45
ROIC/WACCN/A
WACC8.14%

2.3 Liquidity

XMTR has a Current Ratio of 4.28. This indicates that XMTR is financially healthy and has no problem in meeting its short term obligations.
XMTR has a Current ratio of 4.28. This is amongst the best in the industry. XMTR outperforms 94.12% of its industry peers.
XMTR has a Quick Ratio of 4.25. This indicates that XMTR is financially healthy and has no problem in meeting its short term obligations.
XMTR has a Quick ratio of 4.25. This is amongst the best in the industry. XMTR outperforms 98.04% of its industry peers.
Industry RankSector Rank
Current Ratio 4.28
Quick Ratio 4.25

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 52.94% over the past year.
Looking at the last year, XMTR shows a very strong growth in Revenue. The Revenue has grown by 21.58%.
The Revenue has been growing by 48.54% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)52.94%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q96.55%
Revenue 1Y (TTM)21.58%
Revenue growth 3Y48.54%
Revenue growth 5YN/A
Revenue growth Q2Q30.49%

3.2 Future

Based on estimates for the next years, XMTR will show a very strong growth in Earnings Per Share. The EPS will grow by 68.34% on average per year.
The Revenue is expected to grow by 23.14% on average over the next years. This is a very strong growth
EPS Next Y68.43%
EPS Next 2Y75.13%
EPS Next 3Y68.34%
EPS Next 5YN/A
Revenue Next Year16.36%
Revenue Next 2Y18.52%
Revenue Next 3Y18.68%
Revenue Next 5Y23.14%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

1

4. Valuation

4.1 Price/Earnings Ratio

XMTR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for XMTR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as XMTR's earnings are expected to grow with 68.34% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y75.13%
EPS Next 3Y68.34%

0

5. Dividend

5.1 Amount

No dividends for XMTR!.
Industry RankSector Rank
Dividend Yield N/A

XOMETRY INC-A

NASDAQ:XMTR (4/26/2024, 7:25:16 PM)

After market: 17.53 0 (0%)

17.53

+0.61 (+3.61%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryTrading Companies & Distributors
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap851.61M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -9.54%
ROE -20.48%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 38.48%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity 0.86
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 4.28
Quick Ratio 4.25
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)52.94%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y68.43%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)21.58%
Revenue growth 3Y48.54%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y